Condition: Lung Cancer · Sponsor: Hunan Province Tumor Hospital
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
This description comes directly from the study's public registry record.
Yongchang Zhang, MD · +8613873123436 · zhangyongchang@csu.edu.cn
Nong Yang, MD · +8613873123436 · yangnong0217@163.com
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05055908